HIV Articles
Back
	Isentress Once Daily FDA Approval Pending       (Oct 25 2016) The FDA accepted for review a supplemental NDA for a once-daily formulation of ISENTRESS (raltegravir) in combination with other antiretroviral therapies for the treatment of HIV-1 infection in previously untreated patients or patients whose virus remains suppressed after treatment with an initial regimen of 400 mg of ISENTRESS twice-daily. The FDA granted a PDUFA action date of May 27, 2017.....http://www.mrknewsroom.com/news-release/corporate-news/merck-announces-third-quarter-2016-financial-results   Glasgow/2016:Subgroup Analyses from ONCEMRK, a Phase 3 Study of Raltegravir (RAL) 1200 mg Once Daily vs RAL 400 mg Twice Daily, in Combination with Tenofovir/Emtricitabine, in Treatment-Naïve HIV-1 Infected Subjects - (10/26/16)   IAC/2016:Raltegravir (RAL) 1200 mg Once Daily (QD) is Non-Inferior to RAL 400 mg Twice Daily (BID), in Combination with Tenofovir/Emtricitabine, in Treatment-Naïve HIV-1 Infected Subjects: Week 48 Results - (07/29/16)           View Older Articles   Back to Top   www.natap.org